IPG7236

· Nanjing Immunophage Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for IPG7236, covering 2025-09-24 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors [Phase 1, Phase 2]